Immunome INC 10-Q quarterly reports

Immunome, Inc. filed its Form 10-Q for the quarter ended June 30, 2026, detailing increased operating expenses and net losses, alongside progress in its oncology therapy pipeline.

Immunome, Inc. reported its first-quarter 2026 financial results, highlighting continued investment in its oncology pipeline and a strong cash position.

Immunome reports increased cash reserves and pipeline progress for Q3 2025, driven by financing activities and R&D investments, despite continued operating losses.

Immunome, Inc. reports increased R&D spending on key oncology programs and a strong cash position, despite continued operating losses and the termination of its AbbVie collaboration.

Immunome, Inc. announces its financial results for the first quarter of 2025, showcasing increased collaboration revenue and advancements in its clinical pipeline.

Immunome, Inc. reported a net loss of $47.1 million for the third quarter of 2024, driven by increased research and development expenses, while highlighting progress in its clinical and preclinical programs.

Immunome, Inc. reports a net loss of $165.6 million for the first half of 2024, driven by significant investments in research and development and strategic asset acquisitions.

Immunome's first quarter of 2024 saw significant activity, including strategic acquisitions and advancements in its oncology pipeline, alongside a substantial increase in operating expenses.